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Abstract
Background: There are few studies which compare the efficacy and safety of the Resolute Onyx zo-
tarolimus-eluting stent (O-ZES) and everolimus-eluting stent (EES) in patients with acute myocardial 
infarction (AMI). Therefore, the present study aimed to compare clinical outcomes of O-ZES and EES 
in patients with AMI undergoing successful percutaneous coronary intervention (PCI).
Methods: From January 2016 to December 2016, the Korea Acute Myocardial Infarction Registry 
(KAMIR) enrolled 3,364 consecutive patients. Among them, O-ZES was used in 402 patients and EES 
was used in 1,084 patients. The primary endpoint was target lesion failure (TLF), as defined by com-
posite of cardiac death, target vessel myocardial infarction (TV-MI), and ischemic driven-target lesion 
revascularization (ID-TLR) at 6 month clinical follow-up.
Results: At 6 months, the incidence of TLF was not significantly different between O-ZES and EES 
group (4.0% vs. 3.9%, adjusted hazard ratio [HR] 1.17, 95% confidential interval [CI] 0.58–2.35,  
p = 0.665). O-ZES also showed similar results of cardiac death (3.7% vs. 3.4%, adjusted HR 1.25, 95% 
CI 0.59–2.63, p = 0.560), TV-MI (0.2% vs. 0.6%, adjusted HR 0.56, 95% CI 0.07–4.85, p = 0.600), 
ID-TLR (0.0% vs. 0.3%, p = 0.524), and definite or probable stent thrombosis (0.2% vs. 0.3%, adjusted 
HR 0.63, 95% CI 0.06–6.41, p = 0.696) when compared with EES.
Conclusions: The present study shows that implantation of O-ZES or EES provided similar clinical 
outcomes with similar risk at 6-month of TLF and definite/probable ST in patients with AMI undergo-
ing successful PCI. (Cardiol J 2019; 26, 5: 469–476)
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Introduction
Compared with bare-metal stents (BMS), 
drug-eluting stents (DES) have shown better clini-
cal outcomes for patients undergoing percutaneous 
coronary intervention (PCI) by potent prevention 
from neointimal hyperplasia [1]. However, early-
generation DES produced late thrombotic events, 
more than 1-year, by delaying arterial healing 
of stented vessels [2–5]. New-generation DES 
have developed with thinner stent struts, more 
biocompatible polymer coatings for drug release, 
and a variety of antiproliferative agents [6]. This 
development has led to a significant improvement 
in the efficacy and safety  of early-generation DES. 
In recent years, new-generation DES replaced 
early-generation DES because of improved stent 
design, similar or superior anti-restenotic efficacy, 
and consistently lower rates of late stent throm-
bosis (ST) [7, 8]. In fact, currently used DES is 
a standard treatment in modern clinical procedures 
and is used by most patients undergoing PCI. 
Currently, thin strut and durable polymer-
based zotarolimus-eluting stent (ZES) and 
everolimus-eluting stent (EES) are widely used. 
Resolute Onyx-ZES (O-ZES), the latest version 
of ZES, has thinner strut, 81 µm, than Resolute-
ZES (R-ZES), prior version of ZES, which had 
91 µm of strut thickness. R-ZES and EES have 
been directly compared in several randomized 
trials powered for non-inferiority with respect to 
composite clinical endpoints [9–11]. However, 
there are few studies to compare the safety and 
efficacy of O-ZES and EES in patients with acute 
myocardial infarction (AMI). Therefore, the pre-
sent study aimed to compare clinical outcomes of 
O-ZES and EES in patients with AMI undergoing 
successful PCI.
Methods
Study design and patient population
The Korea Acute Myocardial Infarction Regis-
try (KAMIR) is a prospective multicenter registry 
providing observational online data collected and 
designed to examine characteristics, treatment 
practices, and outcomes in patients presenting 
AMI with the support of the Korean Circulation 
Society [12].
Study protocols were approved by the ethics 
committee at each participating center, and fol-
lowed principles of the Declaration of Helsinki. 
Written informed consent was given by each 
patient. If patients were unable to give consent 
because of severity, informed consent was obtained 
from a relative or legal representative.
Among 3,364 patients enrolled in KAMIR 
between January 2016 and December 2016, a total 
of 1,486 patients with AMI were selected who had 
undergone successful PCI with O-ZES (Resolute 
OnyxTM, Medtronic Cardiovascular, Santa Rosa, CA) 
or EES (XIENCETM, Abbot Vascular Santa Clara, 
CA / SYNERGYTM, Boston Scientific, Natick, MA). 
402 patients with AMI were treated with O-ZES 
and 1,084 patients were treated with EES, 620 of 
XIENCETM and 464 of SYNERGYTM (Fig. 1).
Study endpoints, definitions,  
and interventional procedures
The primary endpoint was target lesion failure 
(TLF), being defined as a composite of cardiac 
death, target vessel myocardial infarction (TV-MI), 
and ischemic driven-target lesion revasculariza-
tion (ID-TLR) at 6 months clinical follow-up. The 
secondary endpoints were individual components 
of the TLF and definite/probable ST as defined by 
the Academic Research Consortium [13].
Death was regarded as cardiac in origin unless 
obvious non-cardiac causes could be identified. 
Myocardial infarction (MI) was defined as either the 
development of new pathological Q waves ≥ 0.04 s 
in duration in ≥ 2 contiguous leads or an elevation 
of creatine phosphokinase levels to > 2 times 
normal with positive creatine phosphokinase-MB 
or troponin I or T levels. TV-MI was defined as 
MI attributable to target vessel. TLR was consid-
ered ischemic-driven if associated with a positive 
functional study, a target lesion stenosis ≥ 50% by 
core laboratory quantitative analysis with ischemic 
symptoms or a target lesion stenosis ≥ 70% with 
or without documented ischemia. 
Hypertension was defined as a history of 
hypertension diagnosed and treated with medica-
tion, diet and/or exercise, or blood pressure > 140 
mmHg systolic or 90 mmHg diastolic on at least 
two occasions, or currently on antihypertensive 
pharmacologic therapy. Diabetes mellitus (DM) 
was defined as a history of DM, regardless of 
duration of disease, need for antidiabetic agents, 
or a fasting blood glucose > 126 mg/dL. Family 
history of ischemic heart disease was indicated if 
the patient had any direct blood relatives (parents, 
siblings, children) who had any of the preceeding, 
which were diagnosed at age < 55 years.
All patients who underwent PCI received 
300 mg acetylsalicylic acid (ASA) and 300 or 600 mg 
clopidogrel, or prasugrel 60 mg, or ticagrelor 
180 mg as a loading dose prior to PCI. After PCI, 
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100–300 mg ASA and 75 mg clopidogrel, or 5 or 
10 mg prasugrel one daily or 90 mg ticagrelor twice 
daily were prescribed for maintenance dose. Medi-
cation such as beta-blocker, angiotensin-converting 
enzyme inhibitor (ACEI) or angiotensin II receptor 
blocker (ARB), and statin were prescribed dur-
ing hospitalization and after discharge. Coronary 
artery angiography and stent implantation were 
performed by standard methods. The selection of 
PCI timing, medication, vascular access, use of gly-
coprotein IIb/IIIa inhibitor, use of coronary stents 
were at physician discretion. Clinical follow-up was 
done at 6 months after enrollment.
Statistical analysis
All continuous variables were expressed as 
the mean with standard deviation (SD) or median 
with interquartile ranges (IQR), when appropriate. 
All categorical variables were reported as numbers 
with percentages. The continuous variables were 
compared using the unpaired t-test or Mann-Whit-
ney U test, as appropriate. The categorical vari-
ables were analyzed by using a c2 test or Fisher’s 
exact test. The Cox proportional hazard regression 
modeling (with adjustment for covariates) was 
used to assess clinical outcomes. A Kaplan-Meier 
analysis was performed on data from the O-ZES and 
EES patient groups  to compare 6-month TLF and 
cardiac death, and the difference was determined 
using a log-rank test. Variables had significance 
in univariate analysis (p < 0.100) for endpoints 
which were included in multivariate analysis. The 
following variables were included in multivariate 
Cox regression analysis: age ≥ 65, body mass index 
≥ 25 kg/m2, hypertension, DM, dyslipidemia, family 
history of ischemic heart disease, history of MI, 
history of angina, history of heart failure, history of 
cerebrovascular accident, Killip classification III/IV, 
left ventricular ejection fraction ≤ 50%, left main 
or multivessel disease, image-guided PCI, ACC/ 
/AHA B2/C lesion, pre Thrombolysis In Myocardial 
Infarction (TIMI) flow grade 0/1.
All analyses were two-tailed, and  p value < 0.05 
was considered to reflect significance. All statistical 
analyses were performed using SPSS for Windows 
software (ver. 21.0; SPSS Inc., Chicago, IL, USA).
Results
A total of 1,486 patients with AMI underwent 
successful PCI were included in the present study. 
The average age of the total population was 64.1 ± 
± 12.3 years and 75.4% were men. The mean stent 
diameter was 3.14 ± 0.44 mm and the mean stent 
length was 30.6 ± 15.1 mm. The average number 
of stents used per vessel was 1.22 ± 0.45.
Baseline characteristics and  
coronary angiographic findings 
Mean age was similar for the O-ZES and EES 
group (64.2 ± 12.2 vs. 64.0 ± 12.4, p = 0.802). The 
O-ZES group had higher prevalence of past his-
Figure 1. Patients flow chart, EES — everolimus-eluting stent; KAMIR — Korea Acute Myocardial Infarction Registry; 
O-ZES — Resolute Onyx zotarolimus-eluting stent; PCI — percutaneous coronary intervention.
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tory of MI when compared with EES group (7.5% 
vs. 4.2%, p = 0.010). In laboratory findings, there 
were no significant differences in either group. In 
terms of procedural characteristics, pre-PCI TIMI 
flow grade 0/1 was higher in O-ZES group than in 
EES group (59.5% vs. 53.2%, p = 0.028). In angio-
graphic findings, O-ZES group more frequently had 
left main or multivessel disease than in EES group 
(56.7% vs. 49.0%, p = 0.008). ACEI/ARB was less 
prescribed in the O-ZES group than in the EES 
group (73.6% vs. 78.9%, p = 0.032) (Tables 1, 2).
Six-month clinical outcomes 
The 6-month clinical outcomes did not differ 
between the two groups as shown in Table 3. In Cox 
proportional hazard analysis, O-ZES also showed 
no statistical differences in the incidence of TLF 
(4.0% vs. 3.9%, adjusted hazard ratio [HR] 1.17, 
95% confidential interval [CI] 0.58–2.35, p = 0.665) 
(Fig. 2A), cardiac death (3.7% vs. 3.4%, adjusted 
HR 1.25, 95% CI 0.59–2.63, p = 0.560) (Fig. 2B), 
TV-MI (0.2% vs. 0.6%, adjusted HR 0.56, 95% CI 
0.07–4.85, p = 0.600), ID-TLR (0.0% vs. 0.3%, 
Table 1. Baseline clinical and laboratory characteristics of patients in both groups.
Variables O-ZES (n = 402) EES (n = 1,084) P
Demographic:
Age [years] 64.0 ± 12.4 64.2 ± 12.2 0.802
Male sex 305 (75.9%) 816 (75.3%) 0.813
BMI [kg/m2] 24.2 ± 3.5 24.1 ± 3.4 0.832
Cardiovascular risk factors:
Hypertension 206 (51.2%) 541 (49.9%) 0.647
Diabetes mellitus 122 (30.3%) 294 (27.1%) 0.218
Dyslipidemia 52 (12.9%) 128 (11.8%) 0.554
Current smoking 158 (39.3%) 446 (41.1%) 0.521
Family history of IHD 35 (8.7%) 106 (9.8%) 0.531
Medical history:
Angina 36 (9.0%) 70 (6.5%) 0.097
Myocardial infarction 30 (7.5%) 45 (4.2%) 0.010
Heart failure 5 (1.2%) 11 (1.0%) 0.704
Cerebrovascular accident 24 (9.0%) 73 (6.7%) 0.596
Vital sign on admission:
SBP [mmHg] 131 ± 29 129 ± 29 0.191
DBP [mmHg] 78 ± 18 78 ± 18 0.641
Heart rate [bpm] 79 ±19 78 ± 20 0.474
STEMI 207 (51.5%) 566 (52.2%) 0.805
Killip classification III/IV 58 (14.5%) 151 (14.5%) 0.997
LVEF [%] 52.3 (11.5%) 52.8 (11.2%) 0.388
Laboratory findings:
Total cholesterol [mg/dL] 174 (146–203) 177 (145–206) 0.965
Triglyceride [mg/dL] 110 (81–151) 110 (78–162) 0.360
HDL-cholesterol [mg/dL] 41 (35–52) 42 (35–49) 0.466
LDL-cholesterol [mg/dL] 109 (86–133) 111 (85–138) 0.461
Creatinine [g/dL] 0.9 (0.8–1.1) 0.9 (0.8–1.1) 0.292
hsCRP [mg/dL] 0.30 (0.14–1.07) 0.30 (0.14–1.20) 0.689
Peak CK-MB [ng/mL] 41 (10–170) 51.3 (10–189) 0.160
Peak troponin-I [ng/mL] 18.9 (4.1–40.0) 22.8 (4.8–40) 0.990
Data are expressed as median (interquartile range), mean ± standard deviation or number (percentage) unless otherwise indicated; O-ZES — Reso- 
lute Onyx zotarolimus-eluting stent; EES — everolimus-eluting stent; BMI — body mass index; IHD — ischemic heart disease; SBP — systolic 
blood pressure; DBP — diastolic blood pressure; STEMI — ST-elevation myocardial infarction; LVEF — left ventricular ejection fraction; 
HDL — high-density lipoprotein; LDL — low-density lipoprotein; hsCRP — high-sensitivity C-reactive protein; CK — creatine kinase
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p = 0.524), and definite/probable ST (0.2% vs. 
0.3%, adjusted HR 0.63, 95% CI 0.06–6.41, 
p = 0.696) when compared with EES (Table 3).
Discussion
There have been no studies to directly com-
pare clinical outcomes between O-ZES and EES 
in specific high-risk groups, such as patients with 
AMI. This is the first multicenter and currently the 
largest observational study investigating clinical 
outcomes of AMI patients undergoing success-
ful PCI with O-ZES or EES. The present study 
demonstrates that implantation of O-ZES or EES 
provided similar short-term clinical outcomes in 
patients with AMI undergoing successful PCI.
There are several studies regarding a compari-
son of clinical outcomes after PCI with R-ZES. In 
the RESOLUTE All Comers trial (A Randomized 
Comparison of a Zotarolimus-Eluting Stent with 
an Everolimus-Eluting Stent for Percutaneous 
Coronary Intervention), compared with the EES, 
the TLF did not significantly differ between R-ZES 
and EES in complex patients, such as AMI (8.9% 
in R-ZES group vs. 9.7% in EES group, p = 0.66) 
at 1-year follow-up [14]. In another randomized 
TWENTE trial, complex patients treated with 
R-ZES and EES showed similar TLF during 2-year 
follow-up (11.7% in R-ZES group vs. 10.9% in EES 
group, p = 0.68) [15]. In these two randomized tri-
als, however, patients with AMI were only 43.6% 
and 37.1%, respectively, when compared with the 
Table 2. Characteristics of coronary angiography, procedures and discharge medication between the 
two groups.
Variables O-ZES (n = 402) EES (n = 1,084) P
Trans-radial access 189 (47.0%) 498 (46.3%) 0.802
Image-guided PCI 123 (30.6%) 359 (33.1%) 0.351
Glycoprotein IIb/IIIa inhibitor 45 (11.5%) 163 (15.2%) 0.070
Pre-PCI TIMI flow grade 0/1 237 (59.5%) 573 (53.2%) 0.028
Infarct-related artery: 0.532
Left anterior descending 186 (46.3%) 528 (48.8%)
Left circumflex 65 (16.2%) 180 (16.6%)
Right coronary 140 (34.8%) 337 (31.1%)
Left main 11 (2.7%) 38 (3.5%)
Involved vessel type: 0.008
Single vessel 174 (43.3%) 551 (51.0%)
Left main or multivessel 228 (56.7%) 530 (49.0%)
ACC/AHA B2/C lesion 354 (90.1%) 952 (89.3%) 0.670
Implanted stent:
Stent number 1.25 ± 0.46 1.20 ± 0.45 0.077
Stent diameter [mm] 3.12 ± 0.46 3.15 ±0.43 0.222
Stent length [mm] 31.0 ± 14.8 30.4 ± 15.2 0.498
Medical treatment at discharge:
Acetylsalicylic acid 393 (97.8%) 1,064 (98.2%) 0.626
P2Y12 receptor inhibitor: 393 (97.8%) 1,060 (97.8%) 0.931
Clopidogrel 200 (50.6%) 532 (50.1%)
Ticagrelor 170 (43.0%) 457 (43.0%)
Prasugrel 25 (6.3%) 73 (6.9%)
Statin 371 (92.3%) 1,021 (94.2%)
ACEI/ARB 296 (73.6%) 855 (78.9%) 0.032
Beta-blocker 314 (78.1%) 863 (79.6%) 0.526
Calcium channel blocker 34 (8.5%) 69 (6.4%) 0.158
Data are expressed as mean ± standard deviation or number (percentage) unless otherwise indicated; O-ZES — Resolute Onyx zotarolimus-
eluting stent; EES — everolimus-eluting stent; PCI — percutaneous coronary intervention; TIMI — Thrombolysis In Myocardial Infarction; 
ACC — American College of Cardiology; AHA — American Heart Association; ACEI — angiotensin-converting enzyme inhibitor; ARB — angio-
tensin II receptor blocker.
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present study which enrolled all patients with 
AMI. ST-elevation myocardial infarction (STEMI) 
patients receiving R-ZES had similar 5-year clini-
cal outcomes as compared with those receiving 
EES in the RESOLUTE All Comers trial (TLF, 
7.6% in R-ZES group vs. 10.4% in EES group, 
adjusted p = 0.123; definitive/probable ST, 0.8% 
in R-ZES group vs. 1.3% in EES group, adjusted 
p = 0.868) [16]. In the RESOLUTE Global Clinical 
Trial Program comprising 10 prospective trials, 
R-ZES showed good long-term clinical outcomes. 
In 7618 patients treated with R-ZES, the 5-year 
cumulative incidence of TLF was 13.4%, cardiac 
death 5.0%, TV-MI 4.4%, and ID-TLR 6.3% [17]. 
In the RESOLUTE Global Clinical Trial Program, 
STEMI patients treated with R-ZES also had good 
3-year clinical outcomes, including TLF 9.8%, 
cardiac death 2.9%, TV-MI 1.6%, ID-TLR 7.0%, 
and definite/probable ST 2.8% [16].
Regarding the safety and efficacy of O-ZES, 
O-ZES showed 1-year TLF rate of 4.4% and similar 
efficacy and safety compared with most contempo-
rary DES [18]. O-ZES demonstrated superiority for 
8-month in-stent late lumen loss compared with 
the historical control R-ZES in the RESOLUTE 
ONYX core trial (0.24 ± 0.39 mm with O-ZES 
vs. 0.36 ± 0.52 mm with R-ZES, p = 0.029) [19]. 
Moreover, 2.0 mm O-ZES was associated with a low 
rate of TLF and late lumen loss without definite/
probable ST at 12 month follow-up for treatment 
of coronary lesions with a very small reference 
vessel diameter, less than 2.25 mm in the recent 
study [20]. These favorable clinical outcomes 
including angiographic benefit of O-ZES could be 
explained by characteristics of O-ZES. O-ZES has 
a swaged shape and a larger strut width-to-thick-
ness ratio (strut width 91 µm and thickness 81 µm) 
to maintain radial strength despite thinner strut 






HR 95% CI P HR 95% CI P
Target lesion failure 16 (4.0%) 42 (3.9%) 1.03 0.58–1.83 0.930 1.17 0.58–2.35 0.665
Cardiac death 15 (3.7%) 37 (3.4%) 1.09 0.60–1.99 0.771 1.25 0.59–2.63 0.560
TV-MI 1 (0.2%) 6 (0.6%) 0.45 0.05–3.71 0.456 0.56 0.07–4.85 0.600
ID-TLR 0 (0.0%) 3 (0.3%) 0.524
Definite/probable ST 1 (0.2%) 3 (0.3%) 0.92 0.10–8.79 0.938 0.63 0.06–6.41 0.696
Data are expressed as number (percentage). O-ZES — new developed Resolute Onyx zotarolimus-eluting stent; EES — everolimus-eluting 
stent; HR — hazard ratio; CI — confidence interval; TV-MI — target vessel myocardial infarction; ischemic driven-target lesion revascularization; 
ST — stent thrombosis
Figure 2. Kaplan-Meier curves for 6-month target lesion failure (A) and cardiac death (B) in patients with acute myo-
cardial infarction; EES — everolimus-eluting stent; ZES — zotarolimus-eluting stent.
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when compared with R-ZES. O-ZES also has 
a dense inner core composed of the platinum-iridium 
alloy for increased radiopacity. The enhanced 
radiopacity of O-ZES might have contributed to 
less geographic miss which was associated with 
increased target vessel revascularization [21]. 
Limitations of the study
There were several limitations in the present 
study. First, it was a retrospective study and there 
were possibilities for selection bias. Therefore 
multivariate analysis was undertaken to overcome 
these limitations. Secondly, the number of patients 
included in O-ZES group was relatively small, and 
thus, this study is less robust because of the small 
sample size. Thirdly, EES group included durable 
polymer everolimus-eluting stent (XIENCETM) and 
bioresorbable polymer everolimus-eluting stent 
(SYNERGYTM).  Differing stent features can be 
a possible confounding factor. Finally, interval of 
follow-up was too short to analyze long-term clini-
cal outcomes. Thus, more extensive and long-term 
data are needed.
Conclusions
This study shows that implantation of O-ZES 
or EES provided similar clinical outcomes with sim-
ilar risk of 6-month TLF and definite/probable ST 
in patients with AMI undergoing successful PCI.
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